BioCon-Antibody & PharmaCon China 2022 Innovative Pharmaceuticals Thematic Conference Drew to a Successful Close in Nanjing

The 8th BioCon-Antibody & PharmaCon (BPC) China 2022 Innovative Pharmaceuticals Thematic Conference was successfully held at Marriott Nanjing South Hotel on August 9th and August 10th. LinkChem participated with its pharmaceutical CRO and CDMO service outsourcing business, attracting a large number of visitors.

The BPC Innovative Pharmaceuticals Thematic Conference covered two major themes, BioCon-Antibody and PharmaCon, to create a luxurious tie-up of BPC innovative drugs and propel the future of innovative drugs forward. The conference closely followed the hotspots of global pharmaceutical industry and brought together elites from biopharmaceuticals and chemical pharmaceuticals sectors, with a focus on next-generation double and polyclonal antibodies, ADCs and other drug conjugates, PROTACs, small molecule innovative drugs under AI and other drug categories, from two dimensions of novel antibodies drugs (new targets/ADCs/double and polyclonal antibodies…) and innovative small molecule drugs (PROTACs/AI/CMC/IND/NDA...).

During the conference, over 100 speakers participated in the in-depth discussion of R&D trends and the application of cutting-edge technologies from drug discovery, pre-clinical to clinical development and commercialization, accelerating the development of innovative drugs in China, and assisting domestic pharmaceutical companies in R&D together.

The BPC Innovative Pharmaceuticals Thematic Conference covered two major themes, BioCon-Antibody and PharmaCon, to create a luxurious tie-up of BPC innovative drugs and propel the future of innovative drugs forward. The conference closely followed the hotspots of global pharmaceutical industry and brought together elites from biopharmaceuticals and chemical pharmaceuticals sectors, with a focus on next-generation double and polyclonal antibodies, ADCs and other drug conjugates, PROTACs, small molecule innovative drugs under AI and other drug categories, from two dimensions of novel antibodies drugs (new targets/ADCs/double and polyclonal antibodies…) and innovative small molecule drugs (PROTACs/AI/CMC/IND/NDA...).

During the conference, over 100 speakers participated in the in-depth discussion of R&D trends and the application of cutting-edge technologies from drug discovery, pre-clinical to clinical development and commercialization, accelerating the development of innovative drugs in China, and assisting domestic pharmaceutical.